💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadExplore for free

BRIEF-Concordia International Corp provides business update

Published 2016-12-19, 07:29 a/m
© Reuters.  BRIEF-Concordia International Corp provides business update
ADVZ
-

Dec 19 (Reuters) - Concordia International Corp CXR.TO

* Decided to further reduce expenses by terminating its current contract sales team that was promoting donnatal

* Intends to redirect its resources to other potential pdt with photofrin opportunities

* Announced it will be removed from Nasdaq Biotech Index (nbi) effective prior to market opening on monday

* Paid first installment of its earn-out to Cinven relating to co's october 2015 acquisition of amdipharm mercury limited

* Believes that it has access to sufficient liquidity to meet all of its near term financial obligations

* Termination of company's phase 3 trial for photodynamic therapy with photofrin

* Concordia international corp provides business update Source text for Eikon: ID:nCNWZ5hxza Further company coverage: CXR.TO

(Bangalore.newsroom@thomsonreuters.com)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.